[
  {
    "id": 151,
    "question": "Case scenario of patient with new onset slurred speech and left sided weakness. Symptoms started in the morning, he came to ER in the evening. Brain CT: right hemispheric stroke. BP was 180/95 mmHg. What is the best next step for BP control?",
    "option_a": "IV Hydralazine",
    "option_b": "IV Labetalol",
    "option_c": "No intervention needed",
    "option_d": "Oral Amlodipine",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAcute ischemic stroke is frequently accompanied by a stress-related elevation in blood pressure. Permissive hypertension is a well\u2010recognized compensatory mechanism to maintain cerebral perfusion in the ischemic penumbra.\n\n**Pathophysiology**\n\nAfter an ischemic stroke, cerebral autoregulation may be impaired. The elevated blood pressure helps maintain blood flow to the ischemic regions. Aggressive blood pressure reduction could diminish perfusion to these vulnerable areas, potentially expanding the infarct.\n\n**Clinical Correlation**\n\nThis patient\u2019s blood pressure of 180/95 mmHg is below the thresholds (typically >220/120 mmHg in non-thrombolysed patients) at which immediate pharmacologic lowering is indicated. His presentation, with a right hemispheric infarct on CT and onset several hours earlier, fits the picture where blood pressure is allowed to remain elevated.\n\n**Diagnostic Approach**\n\nIn acute stroke, the differential for hypertension includes a stress response to stroke versus pre-existing chronic hypertension. Blood pressure is carefully monitored and only managed if it exceeds thresholds or if the patient is a candidate for thrombolytic therapy (which requires lower BP).\n\n**Management Principles**\n\nCurrent guidelines recommend not lowering the blood pressure acutely in ischemic stroke patients who are not candidates for thrombolysis, unless systolic BP is >220 mmHg or diastolic BP is >120 mmHg. In pregnant or lactating patients, similar thresholds apply, with careful selection of antihypertensive agents when required. The best approach is often supportive management rather than aggressive BP reduction.\n\n**Option Analysis**\n\nOption A (IV Hydralazine) and Option B (IV Labetalol) are antihypertensives that are used if blood pressure exceeds safety thresholds or in patients undergoing thrombolysis. Option D (Oral Amlodipine) is not appropriate in the acute management phase due to its slower onset. Hence, Option C (No intervention needed) is correct given the patient\u2019s BP relative to guideline thresholds.\n\n**Clinical Pearls**\n\n1. Permissive hypertension in acute ischemic stroke is critical to maintaining perfusion in the ischemic penumbra. 2. Only in patients eligible for thrombolysis or with severely elevated pressures should BP lowering be initiated acutely.\n\n**Current Evidence**\n\nRecent stroke guidelines continue to support a strategy of permissive hypertension in the absence of thrombolysis, emphasizing that overzealous BP lowering may worsen outcomes by reducing perfusion in the ischemic brain.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_3.png"
  },
  {
    "id": 152,
    "question": "Case scenario of patient with symptomatic ICA stenosis. He underwent carotid endarterectomy. Few days later developed new onset confusion and decreased level of consciousness. Urgent brain CT attached. What could explain his current condition?",
    "option_a": "Malignant MCA transformation",
    "option_b": "Cerebral venous thrombosis",
    "option_c": "Hyperperfusion",
    "option_d": "provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nCerebral hyperperfusion syndrome (CHS) is a recognized complication following carotid endarterectomy. It results from a sudden increase in blood flow in cerebral territories that have lost their autoregulatory capacity due to chronic hypoperfusion.\n\n**Pathophysiology**\n\nIn patients with severe carotid stenosis, cerebral vessels distal to the stenosis are chronically dilated to maintain perfusion. After revascularization, these vessels may not be able to constrict appropriately, leading to hyperperfusion. This may result in cerebral edema, hemorrhage, and neurologic deterioration, which explains the patient\u2019s confusion and decreased level of consciousness.\n\n**Clinical Correlation**\n\nThe onset of symptoms a few days after carotid endarterectomy, in a patient with prior symptomatic ICA stenosis, is highly suggestive of CHS rather than thromboembolic events. The clinical picture of altered mental status corresponds with the expected manifestations of hyperperfusion-induced brain injury.\n\n**Diagnostic Approach**\n\nDiagnosis is made clinically, supplemented by imaging studies. CT or MRI may show cerebral edema or even hemorrhage in severe cases, differentiating CHS from other complications such as thromboembolic stroke or malignant MCA infarction. Differential diagnoses include malignant middle cerebral artery (MCA) infarction and cerebral venous thrombosis, but the timing (post-endarterectomy) fits best with hyperperfusion.\n\n**Management Principles**\n\nManagement involves careful blood pressure control to mitigate the risk and severity of hyperperfusion. First-line management includes tight BP control using short-acting intravenous antihypertensives (e.g., labetalol or nicardipine), along with supportive care. In pregnant or lactating patients who undergo carotid procedures (rare), BP management must consider fetal safety, often using agents with well-established safety profiles. Monitoring in an intensive care setting is typically required, and early recognition is paramount to prevent intracerebral hemorrhage.\n\n**Option Analysis**\n\nOption A (Malignant MCA transformation) usually presents with significant mass effect and midline shift; Option B (Cerebral venous thrombosis) has a different clinical and radiologic profile; Option C (Hyperperfusion) is correct as it exactly explains the post-operative scenario. There was no Option D provided.\n\n**Clinical Pearls**\n\n1. After carotid endarterectomy, new neurological deficits with altered mental status should raise the suspicion for cerebral hyperperfusion syndrome. 2. Prevention by meticulous blood pressure control post-surgery is key to reducing the incidence of CHS.\n\n**Current Evidence**\n\nRecent literature supports the use of strict blood pressure management protocols post-carotid revascularization to prevent CHS. Updated guidelines underscore the importance of early detection and management, utilizing continuous BP monitoring and rapidly titratable antihypertensive agents.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_3.png"
  },
  {
    "id": 153,
    "question": "Scenario of acute ischemic stroke, started on IV tPA, 30 minutes later he has headache, vomiting, lethargy, BP 180/100 mmHg. What is the best next step?",
    "option_a": "Brain CT",
    "option_b": "Stop tPA",
    "option_c": "IV Labetalol",
    "option_d": "Close observation",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question tests the recognition and prompt management of a hemorrhagic complication during intravenous thrombolytic therapy (IV tPA) for acute ischemic stroke. The clinical scenario is designed to alert you to the signs of a potential intracerebral hemorrhage developing soon after tPA administration.\n\n**Pathophysiology**\n\ntPA works by promoting fibrinolysis to dissolve clots; however, it also disrupts the blood\u2013brain barrier and local hemostasis. In some patients, especially when blood pressures are high or vessel integrity is compromised, this can lead to a hemorrhagic transformation. The sudden onset of headache, vomiting, and lethargy, along with an elevation in blood pressure, are red flags for intracranial bleeding.\n\n**Clinical Correlation**\n\nThe patient\u2019s neurologic deterioration (lethargy) combined with symptoms of increased intracranial pressure (headache, vomiting) soon after commencement of tPA strongly suggests a hemorrhagic complication. The elevated blood pressure further increases the risk of bleeding. It is essential to act immediately to prevent further hemorrhage.\n\n**Diagnostic Approach**\n\nIn suspected hemorrhagic transformation post-tPA, the immediate step is to stop the tPA infusion to prevent additional thrombolysis and ongoing bleeding. This is then followed by emergent neuroimaging\u2014typically a noncontrast CT scan\u2014to confirm the presence and extent of intracerebral hemorrhage. Differential diagnoses might include reperfusion injury or a stroke progression, but the clinical picture here is most consistent with hemorrhage.\n\n**Management Principles**\n\nImmediate management involves: 1) Stopping the tPA infusion to prevent further bleeding, 2) Urgently obtaining a noncontrast CT scan to confirm hemorrhage, 3) If hemorrhage is confirmed, initiating measures to reverse the fibrinolytic state (commonly via administration of cryoprecipitate or antifibrinolytics) and controlling blood pressure. Guidelines recommend rapidly discontinuing tPA when intracranial hemorrhage is suspected. In pregnant or lactating patients, while imaging (CT scan) is still indicated, appropriate shielding and risk/benefit discussion should be undertaken.\n\n**Option Analysis**\n\n\u2022 Option A (Brain CT): Although CT imaging is essential, it is not the very first step because the tPA infusion must be halted immediately to avoid further bleeding. \\n\u2022 Option B (Stop tPA): This is correct since the immediate cessation of thrombolytic therapy is the highest priority upon suspicion of hemorrhage. \\n\u2022 Option C (IV Labetalol): While blood pressure control is important, using antihypertensives before stopping tPA does not address the ongoing thrombolytic effect. \\n\u2022 Option D (Close observation): Observation is insufficient given the high risk of a life\u2010threatening hemorrhage; immediate intervention is required.\n\n**Clinical Pearls**\n\n\u2022 Any neurological deterioration or signs of raised intracranial pressure during tPA infusion should prompt immediate discontinuation of the drug. \\n\u2022 Elevated BP and symptoms such as headache and vomiting in this setting are highly suspicious for intracerebral hemorrhage.\n\n**Current Evidence**\n\nRecent American Heart Association/American Stroke Association guidelines stress the importance of rapid recognition and management of tPA-induced hemorrhagic complications. Immediate cessation of tPA is universally recommended, followed by urgent neuroimaging to verify the diagnosis and allow for timely intervention.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 154,
    "question": "Direct case scenario of thunderclap headache, CT shows subarachnoid bleed. CTA identified PCom artery aneurysm. Patient is medically free in her 40s. What is the best intervention?",
    "option_a": "Endovascular coiling",
    "option_b": "Surgical clipping",
    "option_c": "Annual follow up",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question tests the recognition and prompt management of a hemorrhagic complication during intravenous thrombolytic therapy (IV tPA) for acute ischemic stroke. The clinical scenario is designed to alert you to the signs of a potential intracerebral hemorrhage developing soon after tPA administration.\n\n**Pathophysiology**\n\ntPA works by promoting fibrinolysis to dissolve clots; however, it also disrupts the blood\u2013brain barrier and local hemostasis. In some patients, especially when blood pressures are high or vessel integrity is compromised, this can lead to a hemorrhagic transformation. The sudden onset of headache, vomiting, and lethargy, along with an elevation in blood pressure, are red flags for intracranial bleeding.\n\n**Clinical Correlation**\n\nThe patient\u2019s neurologic deterioration (lethargy) combined with symptoms of increased intracranial pressure (headache, vomiting) soon after commencement of tPA strongly suggests a hemorrhagic complication. The elevated blood pressure further increases the risk of bleeding. It is essential to act immediately to prevent further hemorrhage.\n\n**Diagnostic Approach**\n\nIn suspected hemorrhagic transformation post-tPA, the immediate step is to stop the tPA infusion to prevent additional thrombolysis and ongoing bleeding. This is then followed by emergent neuroimaging\u2014typically a noncontrast CT scan\u2014to confirm the presence and extent of intracerebral hemorrhage. Differential diagnoses might include reperfusion injury or a stroke progression, but the clinical picture here is most consistent with hemorrhage.\n\n**Management Principles**\n\nImmediate management involves: 1) Stopping the tPA infusion to prevent further bleeding, 2) Urgently obtaining a noncontrast CT scan to confirm hemorrhage, 3) If hemorrhage is confirmed, initiating measures to reverse the fibrinolytic state (commonly via administration of cryoprecipitate or antifibrinolytics) and controlling blood pressure. Guidelines recommend rapidly discontinuing tPA when intracranial hemorrhage is suspected. In pregnant or lactating patients, while imaging (CT scan) is still indicated, appropriate shielding and risk/benefit discussion should be undertaken.\n\n**Option Analysis**\n\n\u2022 Option A (Brain CT): Although CT imaging is essential, it is not the very first step because the tPA infusion must be halted immediately to avoid further bleeding. \\n\u2022 Option B (Stop tPA): This is correct since the immediate cessation of thrombolytic therapy is the highest priority upon suspicion of hemorrhage. \\n\u2022 Option C (IV Labetalol): While blood pressure control is important, using antihypertensives before stopping tPA does not address the ongoing thrombolytic effect. \\n\u2022 Option D (Close observation): Observation is insufficient given the high risk of a life\u2010threatening hemorrhage; immediate intervention is required.\n\n**Clinical Pearls**\n\n\u2022 Any neurological deterioration or signs of raised intracranial pressure during tPA infusion should prompt immediate discontinuation of the drug. \\n\u2022 Elevated BP and symptoms such as headache and vomiting in this setting are highly suspicious for intracerebral hemorrhage.\n\n**Current Evidence**\n\nRecent American Heart Association/American Stroke Association guidelines stress the importance of rapid recognition and management of tPA-induced hemorrhagic complications. Immediate cessation of tPA is universally recommended, followed by urgent neuroimaging to verify the diagnosis and allow for timely intervention.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_3.png"
  },
  {
    "id": 155,
    "question": "Scenario of 65 years old male with multiple cardiovascular risk factors and afib, with 1 day history of right sided dense plegia and aphasia. His brain CT attached. Clinically he is lethargic and poorly communicating. Best next treatment option to consider?",
    "option_a": "Anticoagulation",
    "option_b": "Osmotic therapy",
    "option_c": "Craniotomy/decompression",
    "option_d": "Aspirin",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question tests the recognition and prompt management of a hemorrhagic complication during intravenous thrombolytic therapy (IV tPA) for acute ischemic stroke. The clinical scenario is designed to alert you to the signs of a potential intracerebral hemorrhage developing soon after tPA administration.\n\n**Pathophysiology**\n\ntPA works by promoting fibrinolysis to dissolve clots; however, it also disrupts the blood\u2013brain barrier and local hemostasis. In some patients, especially when blood pressures are high or vessel integrity is compromised, this can lead to a hemorrhagic transformation. The sudden onset of headache, vomiting, and lethargy, along with an elevation in blood pressure, are red flags for intracranial bleeding.\n\n**Clinical Correlation**\n\nThe patient\u2019s neurologic deterioration (lethargy) combined with symptoms of increased intracranial pressure (headache, vomiting) soon after commencement of tPA strongly suggests a hemorrhagic complication. The elevated blood pressure further increases the risk of bleeding. It is essential to act immediately to prevent further hemorrhage.\n\n**Diagnostic Approach**\n\nIn suspected hemorrhagic transformation post-tPA, the immediate step is to stop the tPA infusion to prevent additional thrombolysis and ongoing bleeding. This is then followed by emergent neuroimaging\u2014typically a noncontrast CT scan\u2014to confirm the presence and extent of intracerebral hemorrhage. Differential diagnoses might include reperfusion injury or a stroke progression, but the clinical picture here is most consistent with hemorrhage.\n\n**Management Principles**\n\nImmediate management involves: 1) Stopping the tPA infusion to prevent further bleeding, 2) Urgently obtaining a noncontrast CT scan to confirm hemorrhage, 3) If hemorrhage is confirmed, initiating measures to reverse the fibrinolytic state (commonly via administration of cryoprecipitate or antifibrinolytics) and controlling blood pressure. Guidelines recommend rapidly discontinuing tPA when intracranial hemorrhage is suspected. In pregnant or lactating patients, while imaging (CT scan) is still indicated, appropriate shielding and risk/benefit discussion should be undertaken.\n\n**Option Analysis**\n\n\u2022 Option A (Brain CT): Although CT imaging is essential, it is not the very first step because the tPA infusion must be halted immediately to avoid further bleeding. \\n\u2022 Option B (Stop tPA): This is correct since the immediate cessation of thrombolytic therapy is the highest priority upon suspicion of hemorrhage. \\n\u2022 Option C (IV Labetalol): While blood pressure control is important, using antihypertensives before stopping tPA does not address the ongoing thrombolytic effect. \\n\u2022 Option D (Close observation): Observation is insufficient given the high risk of a life\u2010threatening hemorrhage; immediate intervention is required.\n\n**Clinical Pearls**\n\n\u2022 Any neurological deterioration or signs of raised intracranial pressure during tPA infusion should prompt immediate discontinuation of the drug. \\n\u2022 Elevated BP and symptoms such as headache and vomiting in this setting are highly suspicious for intracerebral hemorrhage.\n\n**Current Evidence**\n\nRecent American Heart Association/American Stroke Association guidelines stress the importance of rapid recognition and management of tPA-induced hemorrhagic complications. Immediate cessation of tPA is universally recommended, followed by urgent neuroimaging to verify the diagnosis and allow for timely intervention.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_3.png"
  },
  {
    "id": 156,
    "question": "Elderly female admitted with stroke. Attached her brain MRI. What else you will find?",
    "option_a": "Left Horner syndrome",
    "option_b": "Left facial sensory loss",
    "option_c": "Left uvula deviation",
    "option_d": "Facial nerve palsy",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question tests the recognition and prompt management of a hemorrhagic complication during intravenous thrombolytic therapy (IV tPA) for acute ischemic stroke. The clinical scenario is designed to alert you to the signs of a potential intracerebral hemorrhage developing soon after tPA administration.\n\n**Pathophysiology**\n\ntPA works by promoting fibrinolysis to dissolve clots; however, it also disrupts the blood\u2013brain barrier and local hemostasis. In some patients, especially when blood pressures are high or vessel integrity is compromised, this can lead to a hemorrhagic transformation. The sudden onset of headache, vomiting, and lethargy, along with an elevation in blood pressure, are red flags for intracranial bleeding.\n\n**Clinical Correlation**\n\nThe patient\u2019s neurologic deterioration (lethargy) combined with symptoms of increased intracranial pressure (headache, vomiting) soon after commencement of tPA strongly suggests a hemorrhagic complication. The elevated blood pressure further increases the risk of bleeding. It is essential to act immediately to prevent further hemorrhage.\n\n**Diagnostic Approach**\n\nIn suspected hemorrhagic transformation post-tPA, the immediate step is to stop the tPA infusion to prevent additional thrombolysis and ongoing bleeding. This is then followed by emergent neuroimaging\u2014typically a noncontrast CT scan\u2014to confirm the presence and extent of intracerebral hemorrhage. Differential diagnoses might include reperfusion injury or a stroke progression, but the clinical picture here is most consistent with hemorrhage.\n\n**Management Principles**\n\nImmediate management involves: 1) Stopping the tPA infusion to prevent further bleeding, 2) Urgently obtaining a noncontrast CT scan to confirm hemorrhage, 3) If hemorrhage is confirmed, initiating measures to reverse the fibrinolytic state (commonly via administration of cryoprecipitate or antifibrinolytics) and controlling blood pressure. Guidelines recommend rapidly discontinuing tPA when intracranial hemorrhage is suspected. In pregnant or lactating patients, while imaging (CT scan) is still indicated, appropriate shielding and risk/benefit discussion should be undertaken.\n\n**Option Analysis**\n\n\u2022 Option A (Brain CT): Although CT imaging is essential, it is not the very first step because the tPA infusion must be halted immediately to avoid further bleeding. \\n\u2022 Option B (Stop tPA): This is correct since the immediate cessation of thrombolytic therapy is the highest priority upon suspicion of hemorrhage. \\n\u2022 Option C (IV Labetalol): While blood pressure control is important, using antihypertensives before stopping tPA does not address the ongoing thrombolytic effect. \\n\u2022 Option D (Close observation): Observation is insufficient given the high risk of a life\u2010threatening hemorrhage; immediate intervention is required.\n\n**Clinical Pearls**\n\n\u2022 Any neurological deterioration or signs of raised intracranial pressure during tPA infusion should prompt immediate discontinuation of the drug. \\n\u2022 Elevated BP and symptoms such as headache and vomiting in this setting are highly suspicious for intracerebral hemorrhage.\n\n**Current Evidence**\n\nRecent American Heart Association/American Stroke Association guidelines stress the importance of rapid recognition and management of tPA-induced hemorrhagic complications. Immediate cessation of tPA is universally recommended, followed by urgent neuroimaging to verify the diagnosis and allow for timely intervention.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_3.png"
  },
  {
    "id": 157,
    "question": "They brought the same scenario in question 28, but they added that: symptoms start to improve, she became following the commands but still has mild weakness and dysarthria. Next step?",
    "option_a": "IV tPA",
    "option_b": "Brain CTA",
    "option_c": "Thrombectomy",
    "option_d": "Dual antiplatelets",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn acute ischemic stroke management, the severity of deficits is critical in guiding therapy. Patients with minor, non\u2010disabling deficits (e.g., mild weakness and dysarthria) who show early improvement are usually managed with secondary prevention measures rather than aggressive reperfusion therapies.\n\n**Pathophysiology**\n\nThe patient\u2019s initial ischemic insult likely led to a partially occluded vessel. Spontaneous reperfusion can occur, resulting in early clinical improvement. However, there remains residual ischemic injury causing mild deficits. The pathophysiologic basis of most minor strokes involves small clot propagation or embolization with limited infarct core.\n\n**Clinical Correlation**\n\nAn improving neurological exam (following commands, residual dysarthria, and mild weakness) suggests that the major ischemic core is potentially limited and the penumbra has been salvaged. This clinical picture classifies her presentation as a minor stroke rather than a severe event that would warrant advanced recanalization imaging or interventions.\n\n**Diagnostic Approach**\n\nThe initial workup in stroke always includes a noncontrast CT to rule out hemorrhage. In patients with severe deficits and suspected large vessel occlusion, CTA plays an essential role. However, in minor strokes with clinical improvement, extensive vascular imaging (like CTA) may not alter immediate management. Differential diagnoses include transient ischemic attack (if symptoms resolve completely), stroke mimics (seizure, migraine, hypoglycemia), or progressive lacunar infarcts, and these are differentiated through detailed history, exam, and imaging.\n\n**Management Principles**\n\nFor minor strokes with non\u2010disabling deficits, the current guidelines recommend initiation of antithrombotic therapy for secondary stroke prevention. A tiered approach is used: first\u2010line therapy is dual antiplatelet therapy (typically aspirin plus clopidogrel) initiated within 24 hours of symptom onset for a short duration (usually 21 to 90 days) based on trials such as CHANCE and POINT. Pregnancy and lactation considerations: Low\u2010dose aspirin is generally considered safe during pregnancy and lactation, though clopidogrel is used with caution and typically avoided in pregnancy unless clearly indicated.\n\n**Option Analysis**\n\nA: IV tPA \u2013 Not indicated here since the patient has already shown improvement and the deficits are minor; tPA\u2019s risk\u2010benefit ratio does not favor its use in minor, non-disabling deficits. B: Brain CTA \u2013 Although vascular imaging is useful in patients suspected of large vessel occlusion, in the context of minor deficits with improvement, CTA is unlikely to change management. C: Thrombectomy \u2013 Reserved for patients with large vessel occlusions and significant deficits, not for minor strokes. D: Dual antiplatelets \u2013 Correct because secondary prevention with dual antiplatelet therapy is the current guideline-recommended approach for minor stroke patients.\n\n**Clinical Pearls**\n\n1) Rapid clinical improvement in stroke does not eliminate the risk of subsequent events; secondary prevention is mandatory. 2) Reperfusion therapies (IV tPA and thrombectomy) are generally reserved for patients with disabling deficits. 3) Dual antiplatelet therapy has been shown to reduce the risk of early recurrent stroke in patients with minor non\u2010disabling ischemic stroke.\n\n**Current Evidence**\n\nRecent large-scale trials (e.g., CHANCE and POINT) have confirmed that short-term dual antiplatelet therapy reduces the risk of recurrent stroke in patients with minor stroke or TIA. Contemporary guidelines support conservative management (antiplatelet therapy) in patients who demonstrate early neurological improvement rather than escalating to advanced imaging like CTA that is geared towards interventional decision-making.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 158,
    "question": "82 years old female, DM/HTN/DLP. Presented with sudden left gaze preference, aphasia, dense right hemiplegia. Her basic labs and INR are fine. She has no contraindications for tPA. Brain CT attached (normal). What is next? NB: time from symptoms onset to ER arrival was 30 minutes.",
    "option_a": "IV tPA",
    "option_b": "Brain CTA",
    "option_c": "Thrombectomy",
    "option_d": "Dual antiplatelets",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAcute ischemic stroke is often diagnosed using a combination of clinical evaluation and imaging. In patients within the therapeutic window (typically within 4.5 hours), IV thrombolysis (tPA) remains the mainstay treatment if no contraindications exist.\n\n**Pathophysiology**\n\nThe occlusion of a cerebral artery leads to a cascade of ischemia, resulting in neuronal injury. In this case, the dense right hemiplegia, aphasia, and left gaze preference suggest a left hemispheric large vessel occlusion. The CT is normal because early ischemic changes might not be visible immediately.\n\n**Clinical Correlation**\n\nThe patient exhibits classical signs of a left middle cerebral artery (MCA) stroke: right hemiplegia, expressive/receptive aphasia, and gaze deviation. The absence of hemorrhage on CT and the clear time window (30 minutes from symptom onset) support the use of IV tPA.\n\n**Diagnostic Approach**\n\nThe initial evaluation involves a rapid noncontrast CT scan to rule out hemorrhage. Differential diagnoses include stroke mimics (e.g., seizure, migraine, hypoglycemia) and hemorrhagic stroke. In this situation, the clinical exam in conjunction with imaging confirms an ischemic stroke.\n\n**Management Principles**\n\nFor eligible patients within 4.5 hours from symptom onset and without contraindications, IV tPA is the first-line therapy. This patient fits those criteria. In addition to thrombolysis, attention should be given to secondary prevention, including antiplatelet therapy, statin therapy, and risk factor modification. Pregnancy and lactation considerations are not applicable in this 82-year-old patient; however, in pregnant patients, IV tPA has been used cautiously when benefits outweigh risks and in the absence of contraindications.\n\n**Option Analysis**\n\nA: IV tPA \u2013 Correct, as the patient is within the time window, has no contraindications and a normal CT ruling out hemorrhage. B: Brain CTA \u2013 While useful in assessing for large vessel occlusion, the primary next step is thrombolysis given her eligibility. C: Thrombectomy \u2013 Reserved for patients with large vessel occlusion who have significant deficits; although it may be considered if CTA shows a treatable occlusion, IV tPA is first-line here. D: Dual antiplatelets \u2013 Secondary prevention is important, but the immediate priority in this acute setting is reperfusion with IV tPA.\n\n**Clinical Pearls**\n\n1) In acute ischemic stroke, time is critical; administering IV tPA within the window significantly improves outcomes. 2) A normal CT does not rule out ischemia; early ischemic changes may take time to appear. 3) Always rule out contraindications before thrombolytic therapy.\n\n**Current Evidence**\n\nLandmark trials such as NINDS and ECASS III have validated the efficacy of IV tPA in acute ischemic stroke when administered within 4.5 hours of symptom onset. Current American Heart Association/American Stroke Association guidelines continue to support this management strategy.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_3.png"
  },
  {
    "id": 159,
    "question": "Elderly female with sudden onset of left gaze preference. She is DM/HTN/DLP. On examination she has persisted left sided gaze preference that couldn't be overcome. What else you might find in her examination?",
    "option_a": "Rt LMN Facial palsy",
    "option_b": "Lt LMN Facial palsy",
    "option_c": "Rt UMN Facial palsy",
    "option_d": "Lt UMN Facial palsy",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nConjugate gaze deviation is a common finding in cortical strokes involving the frontal eye field. In such strokes, the eyes deviate toward the side of the lesion due to loss of contralateral gaze control.\n\n**Pathophysiology**\n\nThe frontal eye field is responsible for directing the eyes contralaterally. When there is an acute infarct (often in the territory of the middle cerebral artery), the loss of inhibitory input causes the eyes to deviate toward the side of the lesion. Moreover, due to the crossing of the corticobulbar pathways, the contralateral lower face exhibits an upper motor neuron (UMN) pattern of weakness.\n\n**Clinical Correlation**\n\nIn this elderly female patient with vascular risk factors, a persistent left gaze preference suggests a left hemispheric cortical involvement. As a result, the right-sided lower facial weakness (UMN type) would be expected. This aligns with the classical neurological examination findings in an MCA distribution stroke.\n\n**Diagnostic Approach**\n\nThe evaluation includes detailed neurological examination and neuroimaging. Differential diagnoses to consider include brainstem lesions, which can also cause gaze abnormalities but typically present with additional cranial nerve deficits, and peripheral facial nerve palsies, which present with lower motor neuron (LMN) patterns.\n\n**Management Principles**\n\nManagement of ischemic strokes includes acute thrombolytic therapy when appropriate, followed by secondary prevention strategies including antiplatelet therapy, risk factor modification, and rehabilitation. In pregnant or lactating patients, while thrombolytic therapy is used with caution, the overall management principles remain similar with adjustments based on risk-benefit assessments.\n\n**Option Analysis**\n\nA: Right LMN Facial palsy \u2013 Incorrect; LMN lesions affect the entire half of the face and are not typically associated with cortical strokes. B: Left LMN Facial palsy \u2013 Incorrect for the same reason and does not correlate with the side of the lesion. C: Right UMN Facial palsy \u2013 Correct; in a left hemispheric stroke, the contralateral (right) lower facial weakness due to an upper motor neuron lesion is the typical finding. D: Left UMN Facial palsy \u2013 Incorrect as this would imply a right hemispheric lesion, conflicting with the left gaze deviation.\n\n**Clinical Pearls**\n\n1) In cortical strokes, gaze deviation is typically toward the side of the lesion. 2) UMN facial weakness spares the forehead due to bilateral cortical innervation. 3) A careful neuro exam correlates well with the affected vascular territory.\n\n**Current Evidence**\n\nRecent studies and guideline recommendations continue to emphasize the importance of correlating clinical findings with imaging to accurately localize strokes. The pattern of gaze preference combined with contralateral UMN facial weakness is a classic and still widely taught sign in acute stroke assessment.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 160,
    "question": "What is the mechanism?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nUnderstanding the mechanism of hemorrhage in the brain is essential. While hypertension is a common etiology for intracerebral hemorrhage, other mechanisms such as coagulopathy directly impair the body\u2019s ability to form clots and thus predispose patients to bleeding.\n\n**Pathophysiology**\n\nIn patients with coagulopathy, whether due to anticoagulant medications, liver disease, or inherent clotting factor deficiencies, the normal coagulation cascade is disrupted. This impairment in hemostasis leads to an increased risk of spontaneous bleeding, including intracerebral hemorrhage. Unlike hypertension-related hemorrhages, which occur from chronic vessel wall damage in deep brain structures, coagulopathy-related bleeds can occur in various brain locations without preceding vessel remodeling.\n\n**Clinical Correlation**\n\nIn the clinical scenario described, the hemorrhage is best explained by a coagulopathic state. This is supported by the absence of the typical deep intracerebral hemorrhage seen with chronic hypertension and the laboratory findings pointing toward coagulation abnormalities.\n\n**Diagnostic Approach**\n\nThe diagnostic workup includes neuroimaging, primarily CT scans, as well as laboratory tests such as prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR). Differential diagnoses include hypertensive hemorrhage and aneurysmal subarachnoid hemorrhage (the latter often presenting with a different clinical picture and hemorrhage pattern). A careful review of the patient\u2019s clinical history and laboratory data helps distinguish these entities.\n\n**Management Principles**\n\nManagement involves rapid reversal of the coagulopathy, supportive care, and stabilization of intracranial pressure. The specific reversal strategy depends on the underlying cause (e.g., vitamin K or fresh frozen plasma for warfarin-related coagulopathy, or specific factor concentrates). In pregnant or lactating patients, careful consideration is needed when administering reversal agents and balancing the risks of hemorrhage against potential adverse effects on the fetus or neonate; multidisciplinary consultation is often warranted.\n\n**Option Analysis**\n\nOption 1 (Hypertension) is incorrect because while hypertension is a leading cause of intracerebral hemorrhage, it operates through chronic vessel wall changes and is not the mechanism in a scenario marked by early coagulation abnormalities. Option 2 (Coagulopathy) is correct because it directly disrupts the clotting cascade, leading to bleeding. Option 3 (Aneurysm) is incorrect; aneurysmal rupture typically results in subarachnoid hemorrhage rather than a parenchymal bleed associated with coagulopathy.\n\n**Clinical Pearls**\n\n1) Always consider a patient\u2019s coagulation status when evaluating spontaneous intracerebral hemorrhage. 2) Coagulopathy can cause intracerebral hemorrhage in the absence of chronic vascular diseases such as hypertension. 3) Prompt identification and reversal of coagulopathy can be life-saving.\n\n**Current Evidence**\n\nRecent guidelines and research underscore the importance of rapid diagnosis and correction of coagulopathy in patients with intracerebral hemorrhage. Studies have demonstrated improved outcomes with faster reversal strategies, and updated protocols emphasize tailored management based on the underlying etiology of the hemorrhage.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]